Opdivo-Yervoy (nivolumab-ipilimumab)
pCPA File Number:
23060
Negotiation Status:
Active Negotiation
Indication(s):
In combination, for the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma when patients progress during or within 6 months of adjuvant PD-1 therapy.
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PX0347-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable